Pharmaceutical

AZD-2389 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Jul 6, 2024 - 04:00
AZD-2389 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Read the original article

Tags:

Previous Article

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (SCA): Likelihood of Approval

Next Article

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Hospices can’t handle the growing number of patients who need wound care

Opinion: Hospices can’t handle the growing number of pa...

Nov 25, 2023

Lupin introduces triple combination Vilfuro-G in India for COPD

Lupin introduces triple combination Vilfuro-G in India ...

Nov 24, 2023

MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win

MSD mulls 2025/26 launch for RSV vaccine after Phase II...

Oct 20, 2024